Find Clinical Trial

Early effect of agomelatine on general interest in outpatients with Major Depressive Disorder. A 12-week, randomized, double-blind, multicentre study with parallel groups: agomelatine (25mg/day given orally with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day given orally with blinded potential adjustment to 20mg/day).

← Back
Study Phase

Phase 3

Therapeutic Area

Neuropsychiatric Diseases

IndicationMajor Depressive Disorder
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device


Active Substance CodeS020098
Protocol CodeCL3-20098-083
EudraCT Code2010-023576-10

Documents and links

Results summary READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.